apl. Prof. Dr. Beatrice Schuler-Thurner

Medizinische Fakultät

Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy (2024) Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, et al. Journal article Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1 (2024) Lindner G, Walter A, Magnus CL, Rosenhammer K, Holoborodko B, Koch V, Hirsch S, et al. Journal article Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity (2023) Müller K, Berking C, Voskens C, Heppt M, Heinzerling L, Koch E, Kramer R, et al. Journal article The future of affordable cancer immunotherapy (2023) Schaft N, Dörrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, Eisenberg G, et al. Journal article, Review article Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial (2023) Koch E, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, et al. Journal article Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis (2022) Voskens C, Stoica D, Rosenberg M, Vitali F, Zundler S, Ganslmayer M, Knott H, et al. Journal article A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma (2022) Koch E, Schaft N, Kummer M, Berking C, Schuler G, Hasumi K, Dörrie J, Schuler-Thurner B Journal article Nectin-1 determines the susceptibility of malignant melanoma to oncolytic herpes simplex virus in vitro and in vivo (2022) Schwertner B, Lindner G, Stauner CT, Klapproth E, Magnus C, Rohrhofer A, Gross S, et al. Conference contribution Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity (2022) Koch E, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial (2021) Voskens C, Stoica D, Roessner S, Vitali F, Zundler S, Rosenberg M, Wiesinger M, et al. Journal article